Financial Contrast: Stoke Therapeutics (STOK) & Its Peers

Stoke Therapeutics (NASDAQ:STOK) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Stoke Therapeutics to similar businesses based on the strength of its earnings, dividends, profitability, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Stoke Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-862.07%	-67.30%	-58.52%
Stoke Therapeutics Competitors	-12,359.35%	-203.09%	-30.93%

Earnings & Valuation

This table compares Stoke Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Stoke Therapeutics	$184.42 million	-$6.89 million	-7.35
Stoke Therapeutics Competitors	$698.09 million	$10.43 million	-15.42

Stoke Therapeutics’ rivals have higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Stoke Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1	0	10	0	2.82
Stoke Therapeutics Competitors	9846	15128	45476	1589	2.54

Stoke Therapeutics presently has a consensus price target of $44.17, suggesting a potential upside of 59.39%. As a group, “Biotechnology” companies have a potential upside of 98.56%. Given Stoke Therapeutics’ rivals higher possible upside, analysts clearly believe Stoke Therapeutics has less favorable growth aspects than its rivals.

Volatility & Risk

Stoke Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Stoke Therapeutics’ rivals have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

47.9% of shares of all “Biotechnology” companies are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Stoke Therapeutics rivals beat Stoke Therapeutics on 7 of the 12 factors compared.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.